EJNMMI Research

Table 1 Percentages of radiolabeled metabolites in plasma after intravenous injection of [¹¹C]CB184

From: Assessment of safety, efficacy, and dosimetry of a novel 18-kDa translocator protein ligand, [¹¹C]CB184, in healthy human volunteers

Time (min)	HM1	HM2	HM3	[¹¹C]CB184	LM1
3	1.4 ± 1.1	1.1 ± 0.7	0.3 ± 0.4	96.1 ± 2.7	1.2 ± 1.0
10	6.4 ± 3.7	8.7 ± 5.6	0.7 ± 0.7	83.8 ± 8.9	0.5 ± 0.6
20	12.2 ± 2.5	20.6 ± 6.0	5.0 ± 2.7	61.6 ± 8.0	0.6 ± 0.4
30	14.9 ± 2.5	25.3 ± 3.5	6.7 ± 3.7	52.9 ± 4.9	0.3 ± 0.3
40	18.4 ± 6.0	26.4 ± 4.8	7.7 ± 3.8	47.0 ± 5.0	0.5 ± 0.4
60	24.0 ± 8.1	29.4 ± 7.2	9.4 ± 3.3	36.7 ± 5.7	0.5 ± 0.7

Data are the mean ± SD for healthy male subjects (n = 5)
HM hydrophilic metabolite, LM lipophilic metabolite

Back to article page